A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice

Sleep Medicine Reviews

Volumn 13, Issue 4, 2009, Pages 265-274

  Krystal, Andrew D ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical practice; Insomnia; Pharmacotherapy; Placebo

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BENZODIAZEPINE; CHLORDIAZEPOXIDE; CLONAZEPAM; DIAZEPAM; DIPHENHYDRAMINE; DOXEPIN; DOXYLAMINE; ESTAZOLAM; ESZOPICLONE; FLURAZEPAM; LORAZEPAM; MIRTAZAPINE; OLANZAPINE; PLACEBO; QUAZEPAM; QUETIAPINE; RAMELTEON; RISPERIDONE; TEMAZEPAM; TRAZODONE; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

CLINICAL TRIAL; COMORBIDITY; CONFUSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MEDICAL DECISION MAKING; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TASTE AVERSION; UNITED STATES; UNPLEASANT SENSATION; XEROSTOMIA;

ADULT; AGED; COMORBIDITY; CONTROLLED CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; EMPIRICISM; HUMANS; HYPNOTICS AND SEDATIVES; RISK ASSESSMENT; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 67549122376     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smrv.2008.08.001     Document Type: Review

References (117)

1. Walsh J.K. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep 27 8 (2004) 14441-14442
2. Walsh J.K., Erman M., Erwin C.W., Jamieson A., Mahowald M., Regestein Q., et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 13 (1998) 191-198
3. Krystal A.D. The changing perspective of chronic insomnia management. J Clin Psychiatry 65 Suppl. 8 (2004) 20-25
4. Hohagen F., Käppler C., Schramm E., Rink K., Weyerer S., Riemann D., et al. Prevalence of insomnia in elderly general practice attenders and the current treatment modalities. Acta Psychiatr Scand 90 (1994) 102-108
5. Hohagen F., Rink K., Käppler C., Schramm E., Riemann D., Weyerer S., et al. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci 242 (1993) 329-336
6. Nowell P.D., Mazumdar S., Buysse D.J., Dew M.A., Reynolds III C.F., and Kupfer D.J. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 278 (1997) 2170-2177
7. Ford D.E., and Kamerow D.B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA 262 (1989) 1479-1484
8. Morin C.M., Bootzin R.R., Buysse D.J., Edinger J.D., Espie C.A., and Lichstein K.L. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998-2004). Sleep 29 11 (2006 Nov 1) 1398-1414
9. Locniskar A., and Greenblatt D.J. Oxidative versus conjugative biotransformation of temazepam. Biopharm Drug Dispos 11 6 (1990 Aug-Sep) 499-506
10. Greenblatt D.J., Harmatz J.S., Engelhardt N., and Shader R.I. Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam. Arch Gen Psychiatry 46 4 (1989 Apr) 326-332
11. Yamazaki A., Kumagai Y., Fujita T., Hasunuma T., Yokota S., Maeda M., et al. Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam. J Clin Pharm Ther 32 1 (2007 Feb) 31-39
12. Miura M., and Ohkubo T. In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica 34 11-12 (2004 Nov-Dec) 1001-1011
13. Greenblatt D.J., Blaskovich P.D., Nuwayser E.S., Harmatz J.S., Chen G., and Zinny M.A. Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. J Clin Pharmacol 45 11 (2005 Nov) 1288-1293
14. Crevoisier C., Delisle M.C., Joseph I., and Foletti G. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Eur Neurol 49 3 (2003) 173-177
15. Nims R.W., Prough R.A., Jones C.R., Stockus D.L., Dragnev K.H., Thomas P.E., et al. In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam. Drug Metab Dispos 25 6 (1997 Jun) 750-756
16. Friedman H., Redmond Jr. D.E., and Greenblatt D.J. Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. Psychopharmacology (Berl) 104 1 (1991) 103-105
17. Fukasawa T., Suzuki A., and Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 32 4 (2007 Aug) 333-341
18. Erdman K., Stypinski D., Combs M., Witt P., Stiles M., and Pollock S. Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet. Pharmacotherapy 27 8 (2007 Aug) 1120-1124
19. Greenblatt D.J., Divoll M.K., Abernethy D.R., Ochs H.R., Harmatz J.S., and Shader R.I. Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. Pharmacology 38 5 (1989) 327-334
20. Gustavson L.E., and Carrigan P.J. The clinical pharmacokinetics of single doses of estazolam. Am J Med 88 3A (1990 Mar 2) 2S-5S
21. Greenblatt D.J., Legangneux E., Harmatz J.S., Weinling E., Freeman J., Rice K., et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 46 12 (2006 Dec) 1469-1480
22. Pichard L., Gillet G., Bonfils C., Domergue J., Thenot J.P., and Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 23 11 (1995 Nov) 1253-1262
23. Greenblatt D.J., Harmatz J.S., von Moltke L.L., Ehrenberg B.L., Harrel L., Corbett K., et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 64 5 (1998 Nov) 553-561
24. Lake B.G., Ball S.E., Kao J., Renwick A.B., Price R.J., and Scatina J.A. Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 32 10 (2002 Oct) 835-847
25. Fernandez C., Maradeix V., Gimenez F., Thuillier A., and Farinotti R. Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 21 6 (1993 Nov-Dec) 1125-1128
26. Ziegler V.E., Biggs J.T., Ardekani A.B., and Rosen S.H. Contribution to the pharmacokinetics of amitriptyline. J Clin Pharmacol 18 10 (1978 Oct) 462-467
27. Richelson E., and Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230 1 (1984 Jul) 94-102
28. Venkatakrishnan K., Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., and Shader R.I. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 38 2 (1998 Feb) 112-121
29. Ghahramani P., Ellis S.W., Lennard M.S., Ramsay L.E., and Tucker G.T. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol 43 2 (1997 Feb) 137-144
30. Karim A., Tolbert D., and Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 46 2 (2006 Feb) 140-148
31. Greenblatt D.J., Harmatz J.S., and Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol 47 4 (2007 Apr) 485-496
32. Kirchheiner J., Meineke I., Muller G., Roots I., and Brockmoller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 12 7 (2002 Oct) 571-580
33. Virtanen R., Scheinin M., and Iisalo E. Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh) 47 5 (1980 Nov) 371-376
34. Miller L.G., Greenblatt D.J., Abernethy D.R., Friedman H., Luu M.D., Paul S.M., et al. Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites. Psychopharmacology (Berl) 94 3 (1988) 386-391
35. Mendelson W.B. Combining pharmacologic and nonpharmacologic therapies for insomnia. J Clin Psychiatry 68 Suppl. 5 (2007) 19-23
36. Greenblatt D.J., Allen M.D., Locniskar A., Harmatz J.S., and Shader R.I. Lorazepam kinetics in the elderly. Clin Pharmacol Ther 26 1 (1979 Jul) 103-113
37. Rotzinger S., Jian F., Coutts R.T., and Baker G.B. Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 44 (1998) 1185-1191
38. Banks W.A., Kastin A.J., Trentman T.L., Haynes H.S., Johnson B.G., and Galina Z.H. Mediation of serotonin-induced analgesia by the 5HT2 receptor in the pentobarbital anesthetized mouse model. Brain Res Bull 21 6 (1988 Dec) 887-891
39. Greenblatt D.J., Friedman H., Burstein E.S., Scavone J.M., Blyden G.T., Ochs H.R., et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 42 2 (1987) 193-200
40. Ishida M., Otani K., Kaneko S., Ohkubo T., Osanai T., Yasui N., et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 10 3 (1995) 143-146
41. Rotzinger S., Bourin M., Akimoto Y., Coutts R.T., and Baker G.B. Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 19 4 (1999 Aug) 427-442
42. Nilsen O.G., and Dale O. Single dose pharmacokinetics of trazodone in healthy subjects. Pharmacol Toxicol 71 2 (1992 Aug) 150-153
43. Cohen M., Panagides J., Timmer C.J., and Huisman J.A. Pharmacokinetics of mirtazapine from orally administered tablets: influence of a high-fat meal. Eur J Drug Metab Pharmacokinet 22 2 (1997 Apr-Jun) 103-110
44. Bookstaff R.C., Murphy V.A., Skare J.A., Minnema D., Sanzgiri U., and Parkinson A. Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice. Toxicol Appl Pharmacol 141 2 (1996 Dec) 584-594
45. Toothaker R.D., Barker S.H., Gillen M.V., Helsinger S.A., Kindberg C.G., Hunt T.L., et al. Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. Biopharm Drug Dispos 21 6 (2000 Sep) 229-233
46. Akutsu T., Kobayashi K., Sakurada K., Ikegaya H., Furihata T., and Chiba K. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos 35 1 (2007 Jan) 72-78
47. Luna B.G., Scavone J.M., and Greenblatt D.J. Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. J Clin Pharmacol 29 3 (1989 Mar) 257-260
48. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
49. Sekine Y., Rikihisa T., Ogata H., Echizen H., and Arakawa Y. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur J Clin Pharmacol 55 8 (1999 Oct) 583-587
50. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 2 (1996 Feb) 87-96
51. He H., and Richardson J.S. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 10 1 (1995 Mar) 19-30
52. Beasley. Olanzapine versus placebo and haloperidol: acute phase results of the north American double-blind olanzapine trial. Neuropsychopharmacology 14 (1996) 111-123
53. Markowitz J.S., DeVane C.L., Malcolm R.J., Gefroh H.A., Wang J.S., Zhu H.J., et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 46 2 (2006 Feb) 164-171
54. Hajak G., Clarenbach P., Fischer W., Haase W., and Ruther E. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol 9 (1994) 251-261
55. Drake C.L., Roehrs T.A., Mangano R.M., and Roth T. Dose-response effects of zaleplon as compared with triazolam (0.25 mg) and placebo in chronic primary insomnia. Hum Psychopharmacol 15 8 (2000 Dec) 595-604
56. Fabre Jr. L.F., Brachfeld J., Meyer L.R., Slowe I.A., Calvo R., and Metzler C. Multi-clinic double-blind comparison of triazolam (Halcion) and placebo administered for 14 consecutive nights in outpatients with insomnia. J Clin Psychiatry 39 8 (1978 Aug) 679-682
57. Nair N.P., Schwartz G., Dimitri R., Le Morvan P., and Thavundayil J.X. A dose-range finding study of zopiclone in insomniac patients. Int Clin Psychopharmacol 5 Suppl. 2 (1990 Apr) 1-10
58. Scharf M.B., Roth P.B., Dominguez R.A., and Ware J.C. Estazolam and flurazepam: a multicenter, placebo-controlled comparative study in outpatients with insomnia. J Clin Pharmacol 30 5 (1990 May) 461-467
59. Walsh J.K., Targum S.D., and Pegram V. A multi-center clinical investigation of estazolam: short-term efficacy. Curr Ther Res 36 (1984) 866-874
60. Aden G.C., and Thatcher C. Quazepam in the short-term treatment of insomnia in outpatients. J Clin Psychiatry 44 12 (1983 Dec) 454-456
61. Fillingim J.M. Double-blind evaluation of the efficacy and safety of temazepam in outpatients with insomnia. Br J Clin Pharmacol 8 1 (1979) 73S-77S
62. Roehrs T., Zorick F., Lord N., Koshorek G.L., and Roth T. Dose-related effects of estazolam on sleep of patients with insomnia. J Clin Psychopharmacol 3 3 (1983 Jun) 152-156
63. Scharf M.B., Roth T., Vogel G.W., and Walsh J.K. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 55 5 (1994 May) 192-199
64. Elie R., Ruther E., Farr I., Emilien G., and Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 60 8 (1999 Aug) 536-544
65. Roth T., Soubrane C., Titeux L., and Walsh J.K. Zoladult Study Group. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. Sleep Med 7 5 (2006 Aug) 397-406
66. Walsh J.K., Vogel G.W., Scharf M., Erman M., William Erwin C., Schweitzer P.K., et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1 1 (2000 Feb 1) 41-49
67. Krystal A.D., Walsh J.K., Laska E., Caron J., Amato D.A., Wessel T.C., et al. Sustained efficacy of eszopiclone over six months of nightly treatment: results of a randomized, double-blind, placebo controlled study in adults with chronic insomnia. Sleep 26 (2003) 793-799
68. Zammit G.K., McNabb L.J., Caron J., Amato D.A., and Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 20 (2004) 1979-1991
69. Roth T., Rogowski R., Hull S., Schwartz H., Koshorek G., Corser B., et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 30 11 (2007) 1555-1561
70. Erman M., Seiden D., Zammit G., Sainati S., and Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 7 1 (2006 Jan) 17-24
71. Rodenbeck A., Cohrs S., Jordan W., Huether G., Ruther E., and Hajak G. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl) 170 4 (2003) 423-428
72. Hajak G., Rodenbeck A., Voderholzer U., Riemann D., Cohrs S., Hohagen F., et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 62 (2001) 453-463
73. Walsh J.K., Roth T., Randazzo A., Erman M., Jamieson A., Scharf M., et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 23 8 (2000 Dec 15) 1087-1096
74. Perlis M.L., McCall W.V., Krystal A.D., and Walsh J.K. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65 8 (2004 Aug) 1128-1137
75. Krystal A.D., Erman M., Zammit G.K., Soubran C., and Roth T. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 31 1 (2008) 79-90
76. Elie R., Frenay M., Le Morvan P., and Bourgouin J. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 5 Suppl. 2 (1990 Apr) 39-46
77. Reeves R.L. Comparison of triazolam, flurazepam, and placebo as hypnotics in geriatric patients with insomnia. J Clin Pharmacol 17 5-6 (1977 May-Jun) 319-323
78. Piccione P., Zorick F., Lutz T., Grissom T., Kramer M., and Roth T. The efficacy of triazolam and chloral hydrate in geriatric insomniacs. J Int Med Res 8 5 (1980) 361-367
79. Sunshine A. Comparison of the hypnotic activity of triazolam, flurazepam hydrochloride, and placebo. Clin Pharmacol Ther 17 5 (1975 May) 573-577
80. Roehrs T., Zorick F., Wittig R., and Roth T. Efficacy of a reduced triazolam dose in elderly insomniacs. Neurobiol Aging 6 4 (1985 Winter) 293-296
81. Morin C.M., Colecchi C., Stone J., Sood R., and Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 281 11 (1999 Mar 17) 991-999
82. Ancoli-Israel S., Walsh J.K., Mangano R.M., and Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1 4 (1999 Aug) 114-120
83. Hedner J., Yaeche R., Emilien G., Farr I., and Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry 15 8 (2000 Aug) 704-712
84. Scharf M., Erman M., Rosenberg R., et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 28 6 (2005) 720-727
85. McCall W.V., Erman M., Krystal A.D., Rosenberg R., Scharf M., and Zammit G.K. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 22 (2006) 1633-1642
86. Lydiard R.B., Lankford D.A., Seiden D.J., Landin R., Farber R., and Walsh J.K. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial. J Clin Sleep Med 2 3 (2006 Jul 15) 309-315
87. Roth T., Seiden D., Wang-Weigand S., and Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 23 5 (2007 May) 1005-1014
88. Roth T., Seiden D., Sainati S., Wang-Weigand S., Zhang J., and Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 7 4 (2006 Jun) 312-318
89. Ancoli-Israel S., Richardson G.S., Mangano R.M., Jenkins L., Hall P., and Jones W.S. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 6 2 (2005 Mar) 107-113
90. Roth T., Walsh J.K., Krystal A., Wessel T., and Roehrs T.A. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6 6 (2005 Nov) 487-495
91. Morgan K. Hypnotics in the elderly: what cause for concern?. Drugs 40 (1990) 688-696
92. Asplund R. Sleep and hypnotic use in relation to perceived somatic and mental health among the elderly. Arch Gerontol Geraitr 31 (2000) 199-205
93. Ohayon M., Caulet M., and Lemoine P. The elderly, sleep habits and use of psychotropic drugs by the French population. Encephale 5 Sep-Oct 22 (1996) 337-350
94. Morgan K., Dallosso H., Ebrahim S., Arie T., and Fentem P.H. Prevalence, frequency and duration of hypnotic use among elderly living at home. Br Med J 296 (1988) 601-602
95. Hayes B., Klein-Schwartz W., and Barrueto Jr. F. Polypharmacy and the geriatric patient. Clin Geriatr Med 23 (2007) 371-390
96. Cook P.J., Huggett A., Graham-Pole R., Savage I.T., and James I.M. Hypnotic accumulation and hangover in elderly inpatients: a controlled double-blind study of temazepam and nitrazepam. Br Med J (Clin Res Ed) 286 6359 (1983 Jan 8) 100-102
97. Mindell J.A., Emslie G., Blumer J., Genel M., Glaze D., Ivanenko A., et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics 117 6 (2006 Jun) e1223-e1232
98. National Institutes of Health. Consensus conference. Drugs and insomnia. The use of medications to promote sleep. JAMA 251 18 (1984) 2410-2414
99. Walsh J.K., Krystal A.D., Amata D.A., Rubens R., Caron J., Wessel T.C., et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 30 8 (2007) 959-968
100. Estivill E. Behavior of insomniacs and implication for their management. Sleep Med Rev 6 Suppl. 1 (2002) S3-S6
101. Perlis M.L., Giles D.E., Buysse D.J., Tu X., and Jupfer D.J. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42 (1997) 209-212
102. Thase M.E. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 60 Suppl. 17 (1999) 28-31 discussion 46-48
103. Tsuno N., Besset A., and Ritchie K. Sleep and depression. J Clin Psychiatry 66 10 (2005) 1254-1269
104. Nierenberg A.A., Keefe B.R., Leslie V.C., Alpert J.E., Pava J.A., Worthington III J.J., et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60 (1999) 221-225
105. Reynolds III C.F., Frank E., Houck P.R., Mazumdar S., Dew M.A., Cornes C., et al. Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication?. Am J Psychiatry 154 7 (1997 Jul) 958-962
106. Nolen W.A., Haffmans P.M., Bouvy P.F., and Duivenvoorden H.J. Hypnotics as concurrent medication in depression. A placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant. J Affect Disord 28 3 (1993 Jul) 179-188
107. Londborg P.D., Smith W.T., Glaudin V., and Painter J.R. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. J Affect Disord 61 (2000) 73-79
108. Fava M., McCall W.V., Krystal A., Rubens R., Caron J., Wessel T., et al. Eszopiclone co-administered with fluoxetine in patients with insomnia co-existing with major depressive disorder. Biol Psychiatry 59 (2006) 1052-1060
109. Krystal A.D., Fava M., Rubens R., Wesel T., Caron J., Wilson P., et al. Evaluation of eszopiclone discontinuation after co-therapy with fluoxetine for insomnia with co-existing depression. J Clin Sleep Med 3 (2007) 48-55
110. Asnis G.M., Chakraburtty A., DuBoff E.A., Krystal A., Londborg P.D., Rosenberg R., et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 60 (1999) 668-676
111. Nierenberg A.A., Adler L.A., Peselow E., Zornberg G., and Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 151 7 (1994 Jul) 1069-1072
112. Pollack M., Kinrys G., Krystal A., McCall W.V., Roth T., Schaefer K., et al. Eszopiclone co-administered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 65 5 (2008) 551-562
113. Walsh J.K., Muehlbach M.J., Lauter S.A., Hilliker N.A., and Schweitzer P.K. Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. J Rheumatol 23 2 (1996 Feb) 245-252
114. Le Bon O., Murphy J.R., Staner L., Hoffmann G., Kormoss N., Kentos M., et al. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol 23 4 (2003 Aug) 377-383
115. Dorsey C.M., Lee K.A., and Scharf M.B. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 26 10 (2004 Oct) 1578-1586
116. Soares C.N., Joffe H., Rubens R., Caron J., Roth T., and Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 108 6 (2006 Dec) 1402-1410
117. Lineberger M.D., Carney C.E., Edinger J.D., and Means M.K. Defining insomnia: quantitative criteria for insomnia severity and frequency. Sleep 29 4 (2006 Apr 1) 479-485